During the last three months, 21 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 11 analysts. The table below summarizes their recent ratings, showcasing the evolving ...
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
In the latest quarter, 9 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...
14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...
One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...
Biogen stock was muted Thursday after the biotech company beat Wall Street's first-quarter expectations, including strong sales for newcomer drugs Leqembi and Skyclarys. Leqembi, which partner Eisai ...
Hosted on MSN
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues ...
Key recent performance and business profile Biogen (BIIB) has moved quietly higher, with the share price showing a 0.8% decline over the last day but gains of 1.5% over the past week and 18.1% over ...
The sale reduced Biogen to 0.03% of reported U.S. equity assets under management as of September 30. Top holdings after the filing: NASDAQ:MSFT: $164.85 million (13.9% of AUM) NASDAQ:AAPL: $122.68 ...
The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates. One of the healthier stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results